Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sirolimus vs Vincristine in High Risk Kaposiform Hemangioendothelioma
NCT02110069Phase 2Terminated
- Sponsor
- Boston Children's Hospital
- Start
- Jun 2017
- Primary completion
- Oct 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of sirolimus in kaposiform hemangioendothelioma (KHE), Kasabach-Merritt syndrome (KMS), tufted angioma (TA), sponsored by Boston Children's Hospital. Started Jun 2017; status: terminated.
02
Drugs
sirolimus
03
Conditions
kaposiform hemangioendothelioma (KHE)Kasabach-Merritt syndrome (KMS)tufted angioma (TA)
Beyond the preview
Go deeper on NCT02110069.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02110069.